Key Takeaways:
- PURE Bioscience reported net product sales of $443,000 for the fiscal second quarter ended January 31, 2026, up from $391,000 in the same period the prior year.
- Net loss for the quarter narrowed to $785,000, compared to $798,000 in the fiscal second quarter of 2025.
- PURE Bioscience received USDA Biobased Product Certification for its new product, PURE® Clean, with an official launch and fulfilment of pre-orders expected in the fiscal third quarter.
- The company is expanding into new verticals including food transportation, dairy, and the biomedical space through a partnership with Quip Laboratories®.
- Distribution partner Bonsai® is using its online platform to broaden access to PURE Bioscience products across business-to-business janitorial, sanitation, and consumer markets.
PURE Bioscience Posts Revenue Growth in Fiscal Second Quarter
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, has reported financial results for the fiscal second quarter ended January 31, 2026.
Net product sales for the quarter reached $443,000, an increase of $52,000 compared to $391,000 in the fiscal second quarter ended January 31, 2025. The company attributed the increase to higher sales across its end-user network.
PURE Bioscience Fiscal Q2 2026 Financial Summary
Quarterly Results
Net loss for the fiscal second quarter ended January 31, 2026 was $785,000, compared to $798,000 for the same period in 2025. Selling, general and administrative expenses decreased by $24,000 due to reductions in board fees and personnel costs, though this was partially offset by increased interest expense related to the company's notes payable balance.
